The FBP vaccine is a composition of E39 peptide combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF).
RXi Pharma president and CEO Mark Ahn said licensing FBP which is already IND- and IRB- approved, and ready to commence two Phase 1 clinical trials in ovarian/endometrial and breast cancers.
"We anticipate initiation of clinical trials this year and are excited about exploring the promising potential of the FBP vaccine in critical areas of unmet medical need," Ahn said.